BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 35798021)

  • 1. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.
    Riazi K; Azhari H; Charette JH; Underwood FE; King JA; Afshar EE; Swain MG; Congly SE; Kaplan GG; Shaheen AA
    Lancet Gastroenterol Hepatol; 2022 Sep; 7(9):851-861. PubMed ID: 35798021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.
    Li J; Zou B; Yeo YH; Feng Y; Xie X; Lee DH; Fujii H; Wu Y; Kam LY; Ji F; Li X; Chien N; Wei M; Ogawa E; Zhao C; Wu X; Stave CD; Henry L; Barnett S; Takahashi H; Furusyo N; Eguchi Y; Hsu YC; Lee TY; Ren W; Qin C; Jun DW; Toyoda H; Wong VW; Cheung R; Zhu Q; Nguyen MH
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):389-398. PubMed ID: 30902670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Ye Q; Zou B; Yeo YH; Li J; Huang DQ; Wu Y; Yang H; Liu C; Kam LY; Tan XXE; Chien N; Trinh S; Henry L; Stave CD; Hosaka T; Cheung RC; Nguyen MH
    Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):739-752. PubMed ID: 32413340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
    Quek J; Chan KE; Wong ZY; Tan C; Tan B; Lim WH; Tan DJH; Tang ASP; Tay P; Xiao J; Yong JN; Zeng RW; Chew NWS; Nah B; Kulkarni A; Siddiqui MS; Dan YY; Wong VW; Sanyal AJ; Noureddin M; Muthiah M; Ng CH
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):20-30. PubMed ID: 36400097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis.
    Liu J; Tian Y; Fu X; Mu C; Yao M; Ni Y; Liu Y; Li Z
    Chin Med J (Engl); 2022 Jul; 135(14):1682-1691. PubMed ID: 36070463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
    Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
    PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
    Younossi ZM; Koenig AB; Abdelatif D; Fazel Y; Henry L; Wymer M
    Hepatology; 2016 Jul; 64(1):73-84. PubMed ID: 26707365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Coffee Consumption on Non-Alcoholic Fatty Liver Disease Incidence, Prevalence and Risk of Significant Liver Fibrosis: Systematic Review with Meta-Analysis of Observational Studies.
    Ebadi M; Ip S; Bhanji RA; Montano-Loza AJ
    Nutrients; 2021 Aug; 13(9):. PubMed ID: 34578919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.
    Mantovani A; Csermely A; Petracca G; Beatrice G; Corey KE; Simon TG; Byrne CD; Targher G
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):903-913. PubMed ID: 34555346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet therapy associated with lower prevalence of advanced liver fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Thongtan T; Deb A; Vutthikraivit W; Laoveeravat P; Mingbunjerdsuk T; Islam S; Islam E
    Indian J Gastroenterol; 2022 Apr; 41(2):119-126. PubMed ID: 35318571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis.
    Wu Y; Zheng Q; Zou B; Yeo YH; Li X; Li J; Xie X; Feng Y; Stave CD; Zhu Q; Cheung R; Nguyen MH
    Hepatol Int; 2020 Mar; 14(2):259-269. PubMed ID: 32130675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.
    Musso G; Gambino R; Tabibian JH; Ekstedt M; Kechagias S; Hamaguchi M; Hultcrantz R; Hagström H; Yoon SK; Charatcharoenwitthaya P; George J; Barrera F; Hafliðadóttir S; Björnsson ES; Armstrong MJ; Hopkins LJ; Gao X; Francque S; Verrijken A; Yilmaz Y; Lindor KD; Charlton M; Haring R; Lerch MM; Rettig R; Völzke H; Ryu S; Li G; Wong LL; Machado M; Cortez-Pinto H; Yasui K; Cassader M
    PLoS Med; 2014 Jul; 11(7):e1001680. PubMed ID: 25050550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons.
    Le MH; Le DM; Baez TC; Wu Y; Ito T; Lee EY; Lee K; Stave CD; Henry L; Barnett SD; Cheung R; Nguyen MH
    J Hepatol; 2023 Aug; 79(2):287-295. PubMed ID: 37040843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
    Younossi ZM; Golabi P; de Avila L; Paik JM; Srishord M; Fukui N; Qiu Y; Burns L; Afendy A; Nader F
    J Hepatol; 2019 Oct; 71(4):793-801. PubMed ID: 31279902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease.
    Alexander M; Loomis AK; Fairburn-Beech J; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Avillach P; Egger P; Kendrick S; Waterworth DM; Sattar N; Alazawi W
    BMC Med; 2018 Aug; 16(1):130. PubMed ID: 30099968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression.
    Orci LA; Sanduzzi-Zamparelli M; Caballol B; Sapena V; Colucci N; Torres F; Bruix J; Reig M; Toso C
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):283-292.e10. PubMed ID: 33965578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
    Zamani M; Alizadeh-Tabari S; Chitkara P; Singh S; Loomba R
    Clin Gastroenterol Hepatol; 2023 Oct; 21(11):2789-2796. PubMed ID: 36871771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis.
    Mantovani A; Turino T; Altomari A; Lonardo A; Zoppini G; Valenti L; Tilg H; Byrne CD; Targher G
    Metabolism; 2019 Jul; 96():56-65. PubMed ID: 31047909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.
    Lazarus JV; Ekstedt M; Marchesini G; Mullen J; Novak K; Pericàs JM; Roel E; Romero-Gómez M; Ratziu V; Tacke F; Cortez-Pinto H; Anstee QM;
    J Hepatol; 2020 Jan; 72(1):14-24. PubMed ID: 31518646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Mantovani A; Nascimbeni F; Lonardo A; Zoppini G; Bonora E; Mantzoros CS; Targher G
    Thyroid; 2018 Oct; 28(10):1270-1284. PubMed ID: 30084737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.